• Galderma Group AG

    ZG
    active
    Check credit rating Timeline
    Check credit ratingCredit rating
    Register number: CH-170.3.046.903-4
    Sector: Operation of investment companies

    Age of the company

    3 years

    Turnover in CHF

    PremiumPremium

    Capital in CHF

    2,0 Mio.

    Employees

    PremiumPremium

    Active brands

    0

    Reports for Galderma Group AG

    *displayed reports are examples
    preview

    Credit rating information

    Evaluation of credit rating with traffic light as risk indicator and other helpful data about the company.
    Find out more
    preview

    Economic information

    Comprehensive information about the economic situation of a company.
    Find out more
    preview

    Payment behaviour

    Assessment of the payment behaviour based on past invoices.
    Find out more
    preview

    Payment collection information

    Overview of current and past debt enforcement proceedings.
    Find out more
    preview

    Shareholder Information

    Find out which national and international companies the stock corporation you are interested in also holds shares in.
    Find out more
    preview

    Company dossier as PDF

    Contact information, changes in the company, turnover and employee figures, management, ownership, shareholding structure and other company data.
    Retrieve company dossier

    About Galderma Group AG

    • Galderma Group AG is currently active and the industry «Operation of investment companies». The legal headquarters are in Zug.
    • The management consists of 11 persons. The company was founded on 07.02.2022.
    • The most recent commercial register change was made on 28.04.2025. You can find all changes under «Notifications».
    • The reported UID is CHE-404.675.624.
    • There are 7 other active companies registered at the same address. These include: Apellis International GmbH, Apellis Schweiz GmbH, EMOTIVE GmbH.

    Commercial register information

    Source: SOGC

    Sector

    Operation of investment companies

    Purpose (Original language)

    Zweck der Gesellschaft ist der Erwerb, das Halten, die Verwaltung, die Verwertung und die Veräusserung von in- und ausländischen Beteiligungen, ob direkt oder indirekt, insbesondere im Bereich des Gesundheitswesens und verwandten Gebieten. Die Gesellschaft kann alle Geschäfte tätigen, die geeignet erscheinen, den Zweck der Gesellschaft zu fördern, oder die mit diesem zusammenhängen. Die Gesellschaft kann Grundstücke und Immaterialgüterrechte im In- und Ausland erwerben, halten, verwalten, belasten, verwerten und verkaufen sowie andere Gesellschaften mit oder ohne Gegenleistung finanzieren.

    Customise the company purpose with just a few clicks.

    Auditor

    Source: SOGC

    Current auditor (1)
    Name City Since Until
    KPMG AG
    Zug 10.02.2022

    Would you like to adjust the auditors? Click here.

    Other company names

    Source: SOGC

    Past and translated company names

    • Galderma Group SA
    • Galderma Group Ltd
    Would you like to update the company name? Click here.

    Branches (0)

    Ownership structure

    No information on the ownership structure is known to us.

    Holdings

    No information on holdings is known to us.

    Newest SOGC notifications: Galderma Group AG

    The latest updates from the Swiss Official Gazette of Commerce (SOGC) are available in the original language of the source commercial register office only. View all notifications

    SOGC 250428/2025 - 28.04.2025
    Categories: Change in management

    Publication number: HR02-1006318203, Commercial Registry Office Zug, (170)

    Galderma Group AG, in Zug, CHE-404.675.624, Aktiengesellschaft (SHAB Nr. 59 vom 25.03.2024, Publ. 1005993463).

    Ausgeschiedene Personen und erloschene Unterschriften:
    Städler, Arthur Hendrik Geerten, von Vex, in Lausanne, Zeichnungsberechtigter, mit Kollektivunterschrift zu zweien.

    SOGC 250324/2025 - 24.03.2025
    Categories: Miscellaneous changes

    Publication number: UP04-0000006903, Commercial Registry Office Zurich

    Category: Notifications issued to company members/nSub-category: Invitation to the General Meeting/nPublication date: SHAB 24.03.2025/nPublicly viewable until: 24.03.2026/nPublication number: UP04-0000006903/nPublishing entity/nAdvestra AG, Uraniastrasse 9.

    8001 Zürich/nCommissioned by:
    /nGalderma Group AG/nInvitation to the ordinary general meeting/nGalderma Group AG/nOrganisation concerned:/nGalderma Group AG/nCHE-404.675.624/nZählerweg 10/n6300 Zug/nGeneral meeting details:/n23.04.2025, 15.00 Uhr, The annual general meeting will be held as a virtual meeting/nwithout a physical venue./nInvitation/Agenda:/nFor the invitation to the annual general meeting and details regarding the annual/ngeneral meeting, please refer to the attachment./nINVITATION 2025/nAnnual/nGeneral Meeting/nof Galderma/nGroup AG/nApril 23, 2025.

    3:
    00 PM CET. Virtual meeting in accordance with/nArt. 12 para. 3 of the Articles of Association./n2AGM Invitation 2025/nLETTER FROM/nTHE CHAIRMAN/nAs we celebrate our first year as a public company,/nI am pleased to invite you to our first Annual General/nMeeting./nDear Shareholders,/nGrowth defined Galderma in 2024./nWith strong innovation pipeline progress and consistent record-breaking net/nsales, we charted the course for the second phase of our growth journey./nBuilding on the success of our initial public offering in March 2024, the/nteam delivered broad-based organic growth spurred by differentiated/ninnovation and commercial excellence. Notably, we achieved significant/nprogress across all three of our resilient, highly attractive and consumer-/nfocused categories of Injectable Aesthetics, Dermatological Skincare and/nTherapeutic Dermatology./nThis performance is a testament to our strong portfolio and the hard work/nof our team. Galderma's dedication to developing a comprehensive, science-/nbased portfolio of premium brands and services enables us to meet the/nmany different needs of individuals across the full spectrum of dermatology./nConsumers, patients and healthcare professionals are increasingly seeking/na holistic approach to skin health. With our proven Integrated Dermatology/nStrategy, we are uniquely positioned in the dermatology category to meet/nand drive market demands./nAs we celebrate our first year as a public company, I am pleased to invite/nyou to our first Annual General Meeting./nThis invitation provides the meeting's full agenda. Among the agenda items/nis the proposed reelection of the current members of the Board of Directors/nand the Compensation Committee. In addition, we will propose the election/nof one new member, Roberto de Oliveira Marques, to both the Board of/nDirectors and the Compensation Committee./nOn behalf of our Board, I thank you, our shareholders, for the trust you/ncontinue to place in us as we advance dermatology for every skin story./nSincerely,/nThomas Ebeling/nChair of the Board of Directors/n3AGM Invitation 2025/n1. APPROVAL OF FINANCIAL STATEMENTS,/nNON-FINANCIAL REPORT AND/nCOMPENSATION REPORT/n1.1 Approval of statutory financial statements/nand consolidated financial statements/nProposal/nThe Board of Directors proposes the approval of the/nstatutory financial statements and the consolidated/nfinancial statements of Galderma Group AG for the/nfinancial year 2024./nExplanation/nThe statutory auditors, KPMG AG, recommend without/nqualification in their report to approve the statutory/nfinancial statements and the consolidated financial/nstatements for the financial year 2024. Therefore, the/nBoard of Directors proposes the approval of the statutory/nfinancial statements and the consolidated financial/nstatements for the financial year 2024./n1.2 Approval of report on non-financial matters/nProposal/nThe Board of Directors proposes the approval of the/nreport on non-financial matters of Galderma Group AG/nfor the financial year 2024./nExplanation/nArt. 964a and 964c of the Swiss Code of Obligations/n(CO) require Galderma Group AG to prepare and submit/na report on non-financial matters to the Annual General/nMeeting for approval. The vote comprises the sections/nspecified on page 152 of Galderma's Annual Report 2024./n1.3 Consultative vote on the compensation report/nProposal/nThe Board of Directors submits a consultative vote on the/ncompensation report for the financial year 2024./nExplanation/nThe Board of Directors submits the compensation/nreport to the Annual General Meeting for a non-binding/nconsultative vote in accordance with Art. 735, para. 3 no./n4 CO and Art. 27, para. 5 of the Articles of Association./n2 APPROPRIATION OF AVAILABLE EARNINGS/nAND DIVIDEND PAYMENT/nProposal/nProposed appropriation of available earnings/nThe Board of Directors proposes the following/nappropriation of available earnings:/nAGENDA AND/nPROPOSALS OF/nTHE BOARD/nOF DIRECTORS/nFor the year ended December 31, 2024/nM/nUSD/nM/nCHF/nAccumulated loss brought forward (0.2) (0.2)/nProfit for the year 18.0 15.8/nCumulative translation adjustment - 51.8/nTotal available earnings 17.8 67.4/nAccumulated profit to be carried forward 17.8 15.6/nCumulative translation adjustment to be/ncarried forward/n- 51.8/nTotal available earnings to be carried/nforward/n17.8 67.4/nNote: Due to rounding, numbers presented throughout this invitation may/nnot add up precisely. For precise figures, please refer to the statutory/nfinancial statements in Galderma's Finance Report 2024./n4AGM Invitation 2025/nProposed dividend payment out of reserves from capital/ncontributions/nThe Board of Directors proposes the following dividend/npayment out of reserves from capital contributions:/nProvided that the proposed dividend payment out of/nreserves from capital contributions is approved, the/npayment will be made as of April 29, 2025 to holders/nof shares on the record date April 28, 2025. The shares/nwill be traded ex-dividend as of April 25, 2025 and,/naccordingly, the last day on which the shares may be/ntraded with entitlement to receive the dividend will be/nApril 24, 2025./nExplanation/nProvided that the proposal of the Board of Directors/nis approved, the dividend out of reserves from capital/ncontributions is expected to amount to 0.15 CHF (gross)/nper share (subject to the conditions set out below) and to/nbe paid as of April 29, 2025/nThe proposed dividend out of reserves from capital/ncontributions will be paid in CHF. The Annual General/nMeeting approves the dividend payment in CHF and the/ncorresponding amount converted to USD. It is envisaged/nthat the CHF amount for the dividend distribution will/nbe converted into USD two business days prior to the/nAnnual General Meeting at the then prevailing exchange/nrate. In order to minimize the risk that the aggregate/nUSD amount converted at the then prevailing exchange/nrate will exceed the aggregate USD amount approved/nfor the dividend payment, the Board of Directors added/na cushion. In the (rather unlikely) event that the amount/nof 49.5 million USD would not be sufficient to distribute/na dividend of 0.15 CHF per share due to unfavorable/nexchange rate fluctuations, the CHF amount would need/nto be reduced to the extent that the aggregate CHF/namount distributed does not exceed 49.5 million USD at/nthe applicable exchange rate./nIn accordance with applicable tax regulations and in/napplication of Art. 5 al. 1ter VStG, up to 50% of the/ndividend will be subject to a 35% Swiss withholding tax,/nwhile the remaining portion of the dividend (at least/n50%) will be paid free from Swiss withholding tax./nGalderma Group AG's auditors, KPMG AG, have audited/nthe proposal regarding the appropriation of available/nearnings and the dividend payment out of reserves/nfrom capital contributions, and have confirmed that the/nproposal of the Board of Directors complies with Swiss/nlaw and the Articles of Association./n3 DISCHARGE OF THE MEMBERS OF THE BOARD/nOF DIRECTORS AND THE EXECUTIVE/nCOMMITTEE FROM LIABILITY/nProposal/nThe Board of Directors proposes to grant discharge to/nthe members of the Board of Directors and the Executive/nCommittee for the financial year 2024./nExplanation/nBased on Art. 698, para. 2 no. 7 CO, the Board of/nDirectors proposes the discharge of the members of the

    SOGC 240325/2024 - 25.03.2024
    Categories: Change in capital

    Publication number: HR02-1005993463, Commercial Registry Office Zug, (170)

    Galderma Group AG, in Zug, CHE-404.675.624, Aktiengesellschaft (SHAB Nr. 53 vom 15.03.2024, Publ. 1005986611).

    Statutenänderung:
    12.03.2024. 21.03.2024.

    Aktienkapital neu:
    CHF 2'378'976.35 [bisher: CHF 2'000'000.00].

    Liberierung Aktienkapital neu:
    CHF 2'378'976.35 [bisher: CHF 2'000'000.00].

    Aktien neu:
    237'897'635 Namenaktien zu CHF 0.01 [bisher: 200'000'000 Namenaktien zu CHF 0.01]. Ordentliche Kapitalerhöhung. [gestrichen: Kapitalband gemäss näherer Umschreibung in den Statuten.]. Kapitalband gemäss näherer Umschreibung in den Statuten. Die Generalversammlung hat mit Beschluss vom 12.03.2024 die Statutenbestimmung über die bedingte Kapitalerhöhung vom 05.03.2024 geändert. [bisher: Die Generalversammlung hat mit Beschluss vom 05.03.2024 ein bedingtes Kapital gemäss näherer Umschreibung in den Statuten eingeführt.]

    Hit list

    Here you will find a link from the management to a hit list of persons with the same name who are registered in the commercial register.

    Title
    Confirm